MARKET

NTLA

NTLA

Intellia Therape
NASDAQ
14.23
-1.21
-7.84%
Opening 11:48 07/10 EDT
OPEN
15.44
PREV CLOSE
15.44
HIGH
15.44
LOW
14.10
VOLUME
3.39M
TURNOVER
--
52 WEEK HIGH
28.25
52 WEEK LOW
7.95
MARKET CAP
1.99B
P/E (TTM)
-4.0269
1D
5D
1M
3M
1Y
5Y
1D
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain
Benzinga · 11h ago
Intellia Therapeutics (NTLA) Gets a Hold from Wedbush
TipRanks · 12h ago
Intellia Therapeutics Price Target Raised to $17.00/Share From $12.00 by Wedbush
Dow Jones · 14h ago
Intellia Therapeutics Is Maintained at Neutral by Wedbush
Dow Jones · 14h ago
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17
Benzinga · 14h ago
Intellia Therapeutics price target raised to $17 from $12 at Wedbush
TipRanks · 14h ago
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
Seeking Alpha · 1d ago
Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/ Ionis
Seeking Alpha · 1d ago
More
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.

Webull offers Intellia Therapeutics Inc stock information, including NASDAQ: NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.